



Decreased Levels of *PIAS* Genes in Periodontitis: A Pilot Study for Finding Possible Contribution of Immune-Related Pathways in Periodontitis

Arezou Sayad¹, Leila Gholami², Elham Badrlou¹, Naghme Nazer³, Sheyda Khalilian¹, Soudeh Ghafouri-Fard⁴, *

¹Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran

²Department of Periodontics, Dental Research Center, Hamadan University of Medical Sciences, Hamadan, Iran

³Department of Electrical Engineering, Sharif University of Technology, Tehran, Iran

⁴Dental Research Center, Research Institute for Dental Sciences, Dental School, Shahid Beheshti University of Medical Sciences, Tehran, Iran

*Corresponding Author: Dental Research Center, Research Institute for Dental Sciences, Dental School, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Email: s.ghafourifard@sbmu.ac.ir

Received: 12 June, 2024; Revised: 30 March, 2025; Accepted: 6 April, 2025

Abstract

Background: Protein inhibitor of activated STAT (*PIAS*) refers to a group of molecules that regulate the transcription of several genes, particularly those involved in modulating immune responses and cytokine production.

Objectives: Given that the development of periodontitis is associated with abnormal levels of several cytokines, we evaluated the potential contribution of *PIAS* genes to the etiology of periodontitis by assessing the transcript levels of these genes in the blood and tissue of affected patients. We also aimed to assess the biomarker roles of these genes.

Methods: In this case-control study, we employed consecutive sampling and included every subject meeting the inclusion criteria over a six-month period. The study comprised 26 cases and 28 controls referred to clinics affiliated with Hamadan University of Medical Sciences during 2022. Gene expression was assessed using quantitative real-time PCR. Differences in the mean expression levels of genes were evaluated using the *t*-test or Mann-Whitney U test.

Results: The *PIAS1* was under-expressed in blood samples obtained from patients compared to control samples (Ratio of mean expression [RME] = 0.49, *P* = 0.04). However, sex-based expression assays revealed no significant difference in its expression between patients and controls (*P* = 0.11 and 0.32 for females and males, respectively). The *PIAS2* levels tended to be lower in total cases (RME = 0.50, *P* = 0.05) and in male patients compared to controls (RME = 0.37, *P* = 0.05). Conversely, *PIAS3* expression tended to be increased in patients' tissues (RME = 2.12, *P* = 0.05). Finally, *PIAS4* had lower transcript levels in the blood of patients versus controls (RME = 0.49, *P* = 0.03), and in female patients versus matched controls (RME = 0.36, *P* = 0.03).

Conclusions: Overall, the altered levels of *PIAS* genes in the circulation of these patients may explain abnormalities in cytokine levels and immune function in the context of periodontitis.

Keywords: Protein Inhibitor of Activated STAT, *PIAS*, Periodontitis, Expression

1. Background

Protein inhibitor of activated STAT (*PIAS*) refers to a group of proteins that regulate the transcription of more than 60 genes. Acting as transcriptional co-regulators, they can either induce or suppress transcription. The *PIAS* proteins cooperate with various transcription factors, including STAT, NF-κB, p73, and p53

(1). In mammals, seven *PIAS* proteins are encoded by the *PIAS1-PIAS4* genes, with each gene coding for two protein isoforms, except for *PIAS1*, which encodes a single isoform (2). Beyond regulating proliferation, differentiation, and apoptotic pathways, *PIAS* genes play a role in modulating immune responses (1). The impact of *PIAS* proteins on immune response is further highlighted by their specificity in modulating the

expression of cytokine-activated proteins (1). Consequently, *PIAS* proteins may have significant effects on the pathogenesis of disorders linked to abnormal cytokine levels (1). Dysregulation of these genes has been observed in patients with migraine (3), bipolar disorder (4), and inflammatory demyelinating polyradiculoneuropathy (5).

Periodontitis is a complex condition associated with inflammatory responses induced by pathogenic bacteria. Persistent inflammatory responses can lead to the destruction of soft tissues and damage to bone structures (6). This condition is characterized by abnormal cytokine levels. Certain cytokines have been implicated in the complex processes associated with soft tissue damage and bone resorption in periodontitis (7). Interleukins 1 β , 4, 6, 10, and 12, as well as IFN- γ , IP-10, and TNF- α , are among the cytokines shown to be elevated during the inflammatory course of periodontitis (8).

2. Objectives

Although bacterial infection may trigger the release of certain cytokines, the primary source of cytokine dysregulation in periodontitis remains unknown. We evaluated the potential influence of *PIAS* genes in the etiology of periodontitis by assessing the transcript levels of these genes in the blood and tissues of affected patients.

3. Methods

3.1. Tissue and Blood Samples

In this case-control study, we consecutively collected samples from 26 cases and 28 controls referred to clinics affiliated with Hamadan University of Medical Sciences during 2022. Cases included patients with stage II to stage IV chronic periodontitis. Tissues were excised from these patients for analysis. The criteria for diagnosing periodontitis were consistent with those used in our previous study (9). All patients were aged 18 or older and had at least 16 teeth. Exclusion criteria included a history of smoking, systemic disorders, or the use of antimicrobial or anti-inflammatory medications. Patients were evaluated by a periodontist in the clinic. Controls were individuals referred for a crown lengthening procedure who showed no signs of periodontitis. The study protocol was approved by the ethical committee of Shahid Beheshti University of Medical Sciences.

3.2. Expression Evaluation

Total RNA was extracted from tissue and blood samples using the PicoPure™ RNA Isolation Kit (Thermo Fisher Scientific), following the guidelines provided in the handbook. Subsequently, cDNA synthesis was performed using the Smobio kit (Taiwan). The relative expressions (RE) of *PIAS* genes were measured using the GeneDireX kit (Taiwan). Reactions were conducted in a LightCycler® 96 system. *HPRT1* was used as the normalizer. The PCR conditions and primers were consistent with those used in previous studies (3, 4).

3.3. Statistical Methods

R software, utilizing the *ggplot2*, *ggfortify*, *ggpubr*, *PROC*, and *caret* packages, was employed to assess the obtained parameters. The *PIAS* gene expressions were measured from Ct and efficiency factors. Since gene expression values were not on a linear scale, all values underwent logarithmic transformation to produce parametric and accurate data. Differences in mean expression levels were evaluated using the *t*-test for normally distributed data and the Mann-Whitney U test as a non-parametric alternative for data that did not follow a normal distribution. The correlation between the expression of *PIAS* genes was assessed using the Spearman correlation coefficient. Receiver operating characteristic (ROC) curves were plotted to evaluate the diagnostic value of *PIAS* genes. Log2 values of the transcript levels of *PIAS* genes were used as predictive features for training three machine learning models with tenfold cross-validation to prevent overfitting, as described previously (10). The area under the curve (AUC) was calculated to identify the best model.

4. Results

The expression of *PIAS* genes was compared between 26 cases and 28 controls. The characteristics of the enrolled individuals are presented in Table 1.


4.1. Expression Assays

The RE levels of *PIAS* genes in the tissues and blood of patients and controls are depicted in Figures 1 and 2, respectively.

The expression of *PIAS1* was significantly lower in blood samples obtained from patients compared to control samples (Ratio of mean expression [RME] = 0.49, $P = 0.04$). However, sex-based expression assays showed no significant difference in its expression between cases and controls ($P = 0.11$ for females and $P = 0.32$ for males). The *PIAS2* levels were also lower in cases compared to controls (RME = 0.50, $P = 0.05$) and in male patients

Table 1. Characteristics of Enrolled Individuals

Parameters	Cases	Controls	P-Values
Total number of tissues	26	28	0.77 ^a
Females	16	12	
Males	10	16	
Age; mean \pm SD	37.6 \pm 2.5	37.5 \pm 1.7	0.86 ^b
Total number of blood samples	23	17	0.91 ^a
Females	15	10	
Males	8	7	
Age; mean \pm SD	38.1 \pm 2.9	37.9 \pm 2.6	0.82 ^b

^a Chi-square test was used.^b *t*-test was used.**Figure 1.** A - D, PIAS1, PIAS2, PIAS3 and PIAS4 expressions in tissues of cases compared with controls (P-values = 0.83, 0.73, 0.05 and 0.17 for PIAS1-4, respectively in total population; P-values = 0.93, 0.84, 0.10 and 0.37 for comparisons in female subgroups; and P-values = 0.97, 0.63, 0.37 and 0.34 for comparisons in male subgroups, respectively).

compared to male controls (RME = 0.37, $P = 0.05$). In contrast, the expression of PIAS3 was increased in the tissues of patients (RME = 2.12, $P = 0.05$). Finally, PIAS4 expression was significantly lower in the blood of patients compared to controls (RME = 0.49, $P = 0.03$), and in female patients compared to female controls (RME = 0.36, $P = 0.03$) (Table 2).

Expressions of PIAS1-4 genes were significantly correlated with each other within each set of samples (blood or gingival tissues). However, the tissue levels of these genes were not correlated with their blood levels (Figure 3). Post hoc tests indicated that, based on the expression differences detected for PIAS3, the estimated

sample size required to achieve a statistical power of 80% is 40 individuals. Therefore, the estimated sample size needed to detect variations in the expression levels of PIAS genes between patients and controls is 40 individuals in each group.

The diagnostic power of PIAS genes both in blood and tissues is shown in Figure 4.

The PIAS1 exhibited the highest area under the curve (AUC) value for differentiating diseased tissues from healthy ones (AUC = 0.70, sensitivity = 0.69, positive predictive value = 0.64). Combining the expression levels of all PIAS genes improved the sensitivity to 0.87, although it did not enhance the AUC value. Similarly,




Figure 2. A - D, Expression of PIAS genes in blood of cases compared with controls (P-values = 0.04, 0.05, 0.08 and 0.03 for PIAS1-4, respectively in total population; P-values = 0.11, 0.35, 0.10 and 0.03 for comparisons in female subgroups; and P-values = 0.32, 0.05, 0.40 and 0.53 for comparisons in male subgroups, respectively).

Table 2. Expression of PIAS Genes in Tissue and Blood of Patients Compared with Controls

Number of Samples	PIAS1 ^a				PIAS2 ^a				PIAS3 ^a				PIAS4 ^a			
	SE	RME	P-Value	95% CI	SE	RME	P-Value	95% CI	SE	RME	P-Value	95% CI	SE	RME	P-Value	95% CI
Tissue (Patients samples/controls samples)																
Total (26/28)	0.55	0.92	0.83	-1.21	0.98	0.60	1.16	0.73	-1.00	1.42	0.54	2.12	0.05	-0.01	2.18	0.70
Female (16/12)	0.87	0.95	0.93	-1.88	1.73	0.97	1.15	0.84	-1.81	2.21	0.81	2.58	0.10	-0.30	3.04	1.11
Male (10/16)	0.70	0.98	0.97	-1.50	1.45	0.73	1.28	0.63	-1.16	1.87	0.80	1.66	0.37	-0.94	2.41	0.74
Blood (Patients samples/controls samples)																
Total (23/17)	0.49	0.49	0.04	-2.05	-0.03	0.49	0.50	0.05	-1.99	0.02	0.60	0.47	0.08	-2.33	0.13	0.47
Female (15/10)	0.73	0.42	0.11	-2.85	0.34	0.70	0.63	0.35	-2.16	0.82	0.85	0.36	0.10	-3.26	0.33	0.62
Male (8/7)	0.63	0.64	0.32	-2.02	0.73	0.65	0.37	0.05	-2.90	0.03	0.72	0.64	0.40	-2.32	1.03	0.65

Abbreviations: RME, ratio of mean expression; PIAS, protein inhibitor of activated STAT.

^a Mann-Whitney U test was used for statistical analyses.

PIAS1 outperformed other genes in distinguishing blood samples of patients from controls (AUC = 0.67, sensitivity = 0.68, positive predictive value = 0.81) (Table 3).

5. Discussion

Periodontitis is an inflammatory condition that leads to the destruction of the periodontal system. This disorder is driven by a series of host-mediated reactions,

including osteoclastogenesis and soft tissue lysis (11). Cytokines play crucial roles in several phases of this process (11). As modulators of cytokine-related pathways (1), PIAS genes are potential contributors to the pathogenesis of periodontitis. However, their role in this disorder has not been thoroughly evaluated.

Our study demonstrated low expression of PIAS1 in the blood of patients compared to control samples, although sex-based expression assays showed no




Figure 3. Correlation between levels of PIAS1, PIAS2, PIAS3 and PIAS4 genes in blood and gingiva. Distribution of parameters is designated on the diagonals. A bivariate scatter plot with a fitted line has been depicted in the lower part of the diagonals to show the correlations. The upper divisions of the diagonal show the r and P -values.

significant difference. The PIAS1 specifically impacts cytokine-mediated pathways through the selective regulation of certain IFN- or TNF-responsive genes (1). It restricts the differentiation of natural regulatory T cells by maintaining a suppressive chromatin configuration

around the *Foxp3* promoter (12). Deletion of both copies of this gene in mice has been associated with an increase in natural regulatory T cells, conferring resistance to the induction of experimental autoimmune encephalomyelitis (12). We have also




Figure 4. A and B, ROC curves of *PIAS* genes in periodontitis (P-values for *PIAS1-4* in blood were 0.04, 0.05, 0.05 and 0.04, respectively. For tissue samples, P-values were 0.09, 0.1, 0.08 and 0.14, respectively).

observed down-regulation of *PIAS1* in inflammatory demyelinating polyradiculoneuropathy (5). Based on *PIAS1*'s role in inhibiting STAT1-mediated IFN signaling (13), we hypothesize that down-regulation of *PIAS1* may enhance immune activation in these patients. Supporting this hypothesis, down-regulation of *PIAS1* has been suggested as a mechanism contributing to allograft rejection (14).

The *PIAS2* levels were lower in cases compared to controls and in male patients compared to controls. The *PIAS2* plays a role in inhibiting IL-12-related STAT4-dependent gene expression activation (15). Since IL-12 is among the up-regulated cytokines during the inflammatory course of periodontitis (8), we hypothesize that down-regulation of *PIAS2* contributes to the etiology of periodontitis by enhancing the expression of this cytokine.

Conversely, *PIAS3* expression tended to be increased in tissues obtained from patients compared to control tissues. In addition to its inhibitory effects on STAT3 signaling (16), *PIAS3* has been shown to modulate osteoclastogenesis by decreasing levels of NFATc1 and the osteoclast-associated receptor (17). Future studies should assess the impact of this axis in the pathogenesis of periodontitis.

Finally, *PIAS4* was under-expressed in the blood of total patients as well as female patients compared to corresponding controls. *PIAS4* suppresses STAT1, LEF1, and SMAD3 pathways (18). Indeed, STAT1 signaling can be suppressed by both *PIAS1* and *PIAS4* proteins (19). Thus, *PIAS1* and *PIAS4*, as the most significantly down-regulated members of this family in the blood of patients with periodontitis, similarly regulate STAT1 signaling.

In addition to their role in STAT signaling, *PIAS* proteins contribute to the regulation of NF- κ B signaling (1). Aberrant expression of numerous genes in the NF- κ B pathway has been reported in periodontitis (20). Moreover, activation of this signaling pathway in an LPS-induced inflammatory niche has been found to suppress the proliferation and differentiation of periodontal ligament stem cells into osteoblasts, thereby contributing to the pathogenesis of periodontitis (21). Therefore, abnormal expression of *PIAS* genes may be involved in the pathoetiology of periodontitis through various mechanisms, including activation of immune responses, modulation of stem cell function, and alterations in the activity of several molecular pathways.

Expressions of *PIAS1-4* genes were significantly correlated with each other within each set of samples (blood or gingiva). However, tissue levels of these genes

were not correlated with their blood levels, indicating the independence of tissue levels of these transcription factors from their blood levels. *PIAS1* exhibited the highest area under the curve (AUC) value for differentiating diseased tissues from healthy ones, as well as for separating blood samples of patients from control blood samples. Thus, *PIAS1* might be considered a marker for the diagnosis of periodontitis.

In summary, altered levels of *PIAS* genes in the circulation of these patients may explain abnormalities in cytokine levels and immune function in the context of periodontitis. However, this hypothesis should be confirmed through functional assays.

Footnotes

Authors' Contribution: S. G. F. wrote the manuscript. S. K. revised it. A. S. designed and supervised the study. L. G. and E. B. performed the experiment. N. N. analyzed the data. All authors read and approved the submitted manuscript.

Conflict of Interests Statement: The authors declare they have no conflict of interests.

Data Availability: The dataset presented in the study is available on request from the corresponding author. The data are not publicly presented due to university policies.

Ethical Approval: All procedures were in accordance with the ethical standards of national research committee and with the 1964 Helsinki declaration. Informed consent forms were obtained from all study participants. The study protocol was approved by the ethical committee of Shahid Beheshti University of Medical Sciences (IR.SBMU.DRC.REC.1400.012)

Funding/Support: This study was supported in part by grant 26841 from the Shahid Beheshti University of Medical Sciences, with the Ethical code of IR.SBMU.DRC.REC.1400.012 .

Informed Consent: The informed consent has provided through our project and is available due to request.

References

- Shuai K, Liu B. Regulation of gene-activation pathways by PIAS proteins in the immune system. *Nat Rev Immunol.* 2005;5(8):593-605. [PubMed ID: 16056253]. <https://doi.org/10.1038/nri1667>.
- Prigge JR, Schmidt EE. Interaction of protein inhibitor of activated STAT (PIAS) proteins with the TATA-binding protein, TBP. *J Biol Chem.* 2006;281(18):12260-9. [PubMed ID: 16522640]. [PubMed Central ID: PMC2030495]. <https://doi.org/10.1074/jbc.M510835200>.
- Ghafouri-Fard S, Hesami O, Nazer N, Sayad A, Taheri M. Expression of PIAS Genes in Migraine Patients. *J Mol Neurosci.* 2021;71(10):2053-9. [PubMed ID: 33763841]. <https://doi.org/10.1007/s12031-021-01834-6>.
- Sayad A, Taheri M, Azari I, Oskoei VK, Ghafouri-Fard S. PIAS genes as disease markers in bipolar disorder. *J Cell Biochem.* 2019;120(8):12937-42. [PubMed ID: 30861611]. <https://doi.org/10.1002/jcb.28564>.
- Ghafouri-Fard S, Hussen BM, Nicknafs F, Nazer N, Sayad A, Taheri M. Expression Analysis of Protein Inhibitor of Activated STAT in Inflammatory Demyelinating Polyradiculoneuropathy. *Front Immunol.* 2021;12:659038. [PubMed ID: 34054823]. [PubMed Central ID: PMC8149797]. <https://doi.org/10.3389/fimmu.2021.659038>.
- Pihlstrom BL, Michalowicz BS, Johnson NW. Periodontal diseases. *Lancet.* 2005;366(9499):1809-20. [PubMed ID: 16298220]. [https://doi.org/10.1016/S0140-6736\(05\)67728-8](https://doi.org/10.1016/S0140-6736(05)67728-8).
- Lindhe J, Lang NP, Karring T. Text Book of clinical Periodontology and implant dentistry. Copenhagen, Denmark: Munksgaard; 2003.
- Cairo F, Nieri M, Gori AM, Tonelli P, Branchi R, Castellani S, et al. Markers of systemic inflammation in periodontal patients: chronic versus aggressive periodontitis. An explorative cross-sectional study. *Eur J Oral Implantol.* 2010;3(2):147-53.
- Gholami L, Ghafouri-Fard S, Mirzajani S, Arsang-Jang S, Taheri M, Dehbani Z, et al. The lncRNA ANRIL is down-regulated in peripheral blood of patients with periodontitis. *Noncoding RNA Res.* 2020;5(2):60-6. [PubMed ID: 32346660]. [PubMed Central ID: PMC7182695]. <https://doi.org/10.1016/j.ncrna.2020.04.001>.
- Behtaji S, Ghafouri-Fard S, Sayad A, Sattari A, Rederstorff M, Taheri M. Identification of oxytocin-related lncRNAs and assessment of their expression in breast cancer. *Sci Rep.* 2021;11(1):6471. [PubMed ID: 33742056]. [PubMed Central ID: PMC7979916]. <https://doi.org/10.1038/s41598-021-86097-2>.
- Graves D. Cytokines that promote periodontal tissue destruction. *J Periodontol.* 2008;79(8 Suppl):1585-91. [PubMed ID: 18673014]. <https://doi.org/10.1902/jop.2008.080183>.
- Liu B, Tahk S, Yee KM, Fan G, Shuai K. The ligase PIAS1 restricts natural regulatory T cell differentiation by epigenetic repression. *Science.* 2010;330(6003):521-5. [PubMed ID: 20966256]. [PubMed Central ID: PMC3043201]. <https://doi.org/10.1126/science.1193787>.
- Liu B, Liao J, Rao X, Kushner SA, Chung CD, Chang DD, et al. Inhibition of Stat1-mediated gene activation by PIAS1. *Proc Natl Acad Sci U S A.* 1998;95(18):10626-31. [PubMed ID: 9724754]. [PubMed Central ID: PMC27945]. <https://doi.org/10.1073/pnas.95.18.10626>.
- Nafar M, Kalantari S, Samavat S, Omrani MD, Arsang-Jang S, Taheri M, et al. Downregulation of Protein Inhibitor of Activated STAT (PIAS) 1 Is Possibly Involved in the Process of Allograft Rejection. *Transplant Proc.* 2020;52(1):414-8. [PubMed ID: 31870601]. <https://doi.org/10.1016/j.transproceed.2019.10.006>.
- Arora T, Liu B, He H, Kim J, Murphy TL, Murphy KM, et al. PIASx is a transcriptional co-repressor of signal transducer and activator of transcription 4. *J Biol Chem.* 2003;278(24):21327-30. [PubMed ID: 12716907]. <https://doi.org/10.1074/jbc.C300119200>.
- Chung CD, Liao J, Liu B, Rao X, Jay P, Berta P, et al. Specific inhibition of Stat3 signal transduction by PIAS3. *Science.* 1997;278(5344):1803-5. [PubMed ID: 9388184]. <https://doi.org/10.1126/science.278.5344.1803>.
- Kim K, Lee J, Kim JH, Jin HM, Zhou B, Lee SY, et al. Protein inhibitor of activated STAT 3 modulates osteoclastogenesis by down-regulation of NFATc1 and osteoclast-associated receptor. *J Immunol.* 2007;178(9):5588-94. [PubMed ID: 17442941]. <https://doi.org/10.4049/jimmunol.178.9.5588>.
- Sachdev S, Bruhn L, Sieber H, Pichler A, Melchior F, Grosschedl R. PIASy, a nuclear matrix-associated SUMO E3 ligase, represses LEF1 activity by sequestration into nuclear bodies. *Genes Dev.*

2001;15(23):3088-103. [PubMed ID: 11731474]. [PubMed Central ID: PMC312834]. <https://doi.org/10.1101/gad.944801>.

19. Liu B, Gross M, ten Hoeve J, Shuai K. A transcriptional corepressor of Stat1 with an essential LXXLL signature motif. *Proc Natl Acad Sci U S A*. 2001;98(6):3203-7. [PubMed ID: 11248056]. [PubMed Central ID: PMC30631]. <https://doi.org/10.1073/pnas.051489598>.

20. Ghafouri-Fard S, Gholami L, Nazer N, Hussen BM, Shadnoush M, Sayad A, et al. Assessment of expression of NF-κB-related genes in periodontitis. *Gene Reports*. 2022;26. <https://doi.org/10.1016/j.genrep.2021.101454>.

21. Chen M, Lin X, Zhang L, Hu X. Effects of nuclear factor-kappaB signaling pathway on periodontal ligament stem cells under lipopolysaccharide-induced inflammation. *Bioengineered*. 2022;13(3):7951-61. [PubMed ID: 35297308]. [PubMed Central ID: PMC9208442]. <https://doi.org/10.1080/21655979.2022.2051690>.

Table 3. ROC Curve Analysis in the Tissues and Blood

Variables	PIAS1			PIAS2			PIAS3			PIAS4			All			
	AUC	Sensitivity	Positive predictive value	AUC	Sensitivity	Positive predictive value	p ^a									
Tissue	0.70	0.69	0.64	0.09	0.60	0.30	0.68	0.1	0.62	0.61	0.67	0.08	0.53	0.66	0.53	0.14
Blood	0.67	0.68	0.81	0.04	0.63	0.53	0.73	0.05	0.61	0.66	0.70	0.05	0.65	0.76	0.74	0.04

Abbreviations: PIAS, protein inhibitor of activated STAT.

^a Two tailed P-values are presented.